Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.

Slides:



Advertisements
Similar presentations
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà
Advertisements

Diastolic Heart Failure, HFpEF, HFnEF: What are we treating anyway? Charles M. Rasmussen, MD FACC.
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
GOLD Clasification Antonio Anzueto MD Professor Medicine University of Texas.
Dr. Danny Galdermans Dept Respiratory Medicine ZNA Middelheim Antwerp
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Heart rate reduction with ivabradine and health related quality of life in.
Dorset Improving Diagnosis of Heart Failure Implementation of BNP Measuring in General Practice Ist Project Steering Group 13 th Sept 2011.
Loop diuretics VS venous ultrafiltration in cardio-renal syndrome Radek Debiec SHO Renal Medicine LGH Sept 2013.
Pulmonary Rehabilitation In COPD
Heart Failure and Qof Quiz Justin Walker October 2010.
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.
Clinical Impact of Adherence to Pharmacotherapeutic Guidelines on the Outcome in Patients with Chronic Heart Failure Suntheep Batra, M.Pharm Department.
CVD and co-morbidities What are the priorities? G.J. Geersing, General Practitioner MD PhD Julius Center UMC Utrecht EPCCS conference 2014 Groningen.
HEART FAILURE Prevalence increasing in our ageing population Incidence doubles with each decade between 40 and 80 At any age more common in men than women.
L References Application to Clinical Practice The American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have cooperatively.
Randomized, double-blind, multicenter, controlled trial.
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
Management of Stable Angina SIGN 96
Clinical Outcomes with Newer Antihyperglycemic Agents
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
Continence and older adults Mark Weatherall University of Otago Wellington.
Specialized Atrial Fibrillation Clinic reduces cardiovascular morbidity and mortality in patients with atrial fibrillation Jeroen ML Hendriks, MSc Robert.
Background, recognition and differentials. By Dr L Axten.
The Detrimental Effects of Anxiety Secondary to COPD and its facilitation of Disease Progression and Decreased Quality of Life Ashley Anglin.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
Comorbidities and Diabetes Care – Impact on Treatment Strategies Dr. Joel Rodriguez-Saldana Multidisciplinary Diabetes Centres Mexico.
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
M. JESSUP Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.
GOLD Update 2011 Rabab A. El Wahsh, MD. Lecturer of Chest Diseases and Tuberculosis Minoufiya University REVISED 2011.
The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.
Are patients with chronic diseases a new challenge to general practice? Do patients with severe COPD need 6-monthly check-ups at their general practitioner?
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure Systolic Heart.
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
Heart failure and comorbidities
Preoperative Hemoglobin A1c and the Occurrence of Atrial Fibrillation Following On-pump Coronary Artery Bypass surgery in Type-2 Diabetic Patients Akbar.
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
Impact of Multidisciplinary Team Care on Older People with Polypharmacy Liang-Kung Chen Center for Geriatrics and Gerontology Taipei Veterans General Hospital.
New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Find out more online: Improving the quality of respiratory care Dr Felix Blaine.
NTproBNP for the Exclusion of Heart Failure Richard Blakey.
Increased Patient Device Concerns But Not General Anxiety in Patients with a Secondary Indication for the ICD Susanne S. Pedersen, Professor of Cardiac.
Are the European Practice Guidelines for the Management of Arterial Hypertension (2007) adapted to the old and the frail? Anette Hylen
CoRPS Disclosures None. CoRPS Center of Research on Psychology in Somatic diseases Impact of psychological profile in heart failure patients Susanne S.
WELCOME BNP testing. Aims of this education package Better understanding of what BNP testing is How to appropriately use the test How to request the.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Original article Chronic Renal Failure A Neglected Comorbidity of COPD Raffaele Antonelli Incalzi, MD; Andrea Corsonello, MD; Claudio Pedone, MD; Salvatore.
HF diagnosis: audit of NTproBNP uptake and outcomes across Sheffield An update on diagnosis and management of HF Dr Abdallah Al-Mohammad, MD, FRCP(Edin),
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Has Public Reporting of Hospital Readmission Rates.
CoRPS Center of Research on Psychology in Somatic diseases Brief Depression Screening with the PHQ-2 Predicts Poor Prognosis following PCI with Drug-Eluting.
Angela Aziz Donnelly April 5, 2016
Chronic heart failure By Vishal Patel GPVTS1.
DIAGNOSIS No symptoms = no heart failure. DIAGNOSIS No symptoms = no heart failure.
Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital
Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.
European Heart Association Journal 2007 April
Occurrence of morning symptoms
Diagnosi della BPCO 1.
Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.
Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. Morbidity and mortality benefits with statin use in observational.
Distribution of NEWS in the community by service
Presentation transcript:

Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà dell’autore e fornito come supporto didattico per uso personale.

Cardiology & Respiratory Medicine, Hvidovre Hospital COPD in patients with chronic diseases Jørgen Vestbo Respiratory Section, Hvidovre Hospital / University of Copenhagen, DK. Manchester Academic Health Sciences Centre, University of Manchester, UK.

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital  I have received honoraria for presenting and advising from several pharmaceutical companies  I hold research grants from GSK  My wife has worked for several pharmaceutical companies Disclosure of Interest

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital Fjellanger et al, Tidsskr Nor Lægeforen 2003 Effect of comorbidities on COPD prognosis Follow-up (months) 1+ comorbidities No comorbidities Women Survival (%) Follow-up (months) 1+ comorbidities No comorbidities Men Survival (%)

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital  Cardiovascular disease  Osteoporosis  Depression  … Comorbidities of particular interest in COPD

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital  In cardiovascular disease  In depression  In all patients eligible for rehabilitation including physical exercise  In the elderly When is COPD of particular interest ?

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital RR in COPD versus non-COPD Rate per 10,000 Angina, 1.67 Myocardial Infarction, 1.75 Osteoporosis, 3.14 Respiratory Infection, 2.24 Fractures, 1.58 Glaucoma, 1.29 Cataracts, 0.90 COPD and comorbidities UK General Practice Research Database Soriano et al, Chest 2005.

Modena March 2011 COPD + HF, Scotland Cardiology & Respiratory Medicine, Hvidovre Hospital Hawkins et al, Eur J Heart Fail 2010.

Modena March 2011 COPD + HF, Scotland Cardiology & Respiratory Medicine, Hvidovre Hospital Hawkins et al, Eur J Heart Fail 2010.

Modena March 2011 COPD + HF, UK Cardiology & Respiratory Medicine, Hvidovre Hospital NICE Guidelines on Heart Failure 2010 Five papers were identified comparing beta-blockers with placebo in older adults with chronic heart failure 55,56,57,58,59.

Modena March 2011 COPD + HF, UK Cardiology & Respiratory Medicine, Hvidovre Hospital NICE Guidelines on Heart Failure 2010 Five papers were identified comparing beta-blockers with placebo in older adults with chronic heart failure 55,56,57,58, Patients with COPD were excluded in all studies except one study 58.

Modena March 2011 COPD + HF, UK Cardiology & Respiratory Medicine, Hvidovre Hospital NICE Guidelines on Heart Failure 2010

Modena March 2011 COPD + HF, UK Orthopnoea Cardiology & Respiratory Medicine, Hvidovre Hospital NICE Guidelines on Heart Failure 2010

Modena March 2011 COPD + HF, UK Natriuretic peptides Non-HF causes of high NP. LVH, ischaemia, tachycardia, RV overload, hypoxaemia (including pulmonary embolism), renal dysfunction (eGFR 70 years), cirrhosis of the liver. Factors causing low NP. Obesity and treatment with diuretics, ACEI, BB, ARB and AA. Cardiology & Respiratory Medicine, Hvidovre Hospital NICE Guidelines on Heart Failure 2010

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital Consecutive patients (n = 532) with symptomer of heart failure NYHA class III-IV admitted with Heart failure and treated with diuretics. Iversen et al, J Intern Med COPD and acute HF

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital Consecutive patients (n = 532) with symptomer of heart failure NYHA class III-IV admitted with Heart failure and treated with diuretics. COPD was only known in 43% of patients with COPD according to spirometry; 33% af patients claiming to have COPD did not have airflow limitation. Iversen et al, J Intern Med COPD and acute HF

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital COPD and prognosis in HF ECHOS study, 532 patients Iversen et al, Eur J Heart Fail 2010

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital COPD and Atrial Fibrillation Buch et al, ERJ 2003.

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital Clinical consequenses of osteoporosis Loss of Quality of Life (All)  Loss of mobility (1/2)  Loss of independence (1/3)

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital COPD and depression nChanges in mood often under-diagnosed nHigh prevalence of anxiety and depression in COPD patents (Kunick, 2005) nRelated to the rate of the emergency treatment for COPD exacerbation (Dahlen, 2002) nAfter discharge, patients with higher SGRQ score showed in the follow-up a higher risk of exacerbation (Gudsmusson, 2005)

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital Dahlen et al, Chest Anxiety/depression are associated with poor prognosis in COPD patients p<0.05 No anxiety/depression Probable anxiety and/or depression Time, days % of patients without treatment failure

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital Exercise Capacity Limitation and Depression in COPD 6 MWD COPD [N=106, FEV 1 =52 %] K Al-Shair et al. Respir Med Depression scales [CES-D, BASDEC] 6MWD  350m < 350mp CES-D BASDEC

Modena March 2011 Depression in adults with a chronic physical health problem Implementing NICE guidance 2009 NICE clinical guideline 91

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital COPD and depression NICE Guidelines on Depression in Adults with a Chronic Health Problem 2010

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital COPD and depression NICE Guidelines on Depression in Adults with a Chronic Health Problem 2010

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital COPD, depression and rehabilitation Clinical observation

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital Mobilisation and Rehabilitation

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital Mobilisation and Rehabilitation Cataract (37%), deafness (31%) and osteoarthritis of the knee (29%) were the most frequent non-CV comorbidities. COPD was No 4 (24.5%) van der Wel et al. Eur J Heart Fail 2007.

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital Mobilisation and Rehabilitation Cataract (37%), deafness (31%) and osteoarthritis of the knee (29%) were the most frequent non-CV comorbidities. COPD was No 4 (24.5%) – no spirometry ! van der Wel et al. Eur J Heart Fail 2007.

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital COPD and the elderly

Modena March 2011 Polypharmacy Polypharmacy can be  Necessary  Un-necessary ”Good polypharmacy”  Type 2 diabetes  Heart failure Cardiology & Respiratory Medicine, Hvidovre Hospital

Modena March 2011 Polypharmacy The general rules  Think NNT critically  Primary ASA prophylaxis, NNT for MI (5yrs) 200, NNH for severe bleeding 150  Consider if new symptoms could be side effects to existing therapy  Follow-up crucial Cardiology & Respiratory Medicine, Hvidovre Hospital

Modena March 2011 Polypharmacy The general rules  Think NNT critically  Primary ASA prophylaxis, NNT for MI (5yrs) 200, NNH for severe bleeding 150  Consider if new symptoms could be side effects to existing therapy  Follow-up crucial  Problems with adherence increase exponentially from 4+ drugs Cardiology & Respiratory Medicine, Hvidovre Hospital

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital COPD and adherence

Modena March 2011 Conclusions  COPD is a frequent comorbidity in many chronic diseases  COPD will have an impact on treatment and outcomes in many chronic disease  Expect COPD to be overlooked  ”Thing polypharmacy and adherence” Cardiology & Respiratory Medicine, Hvidovre Hospital

Modena March 2011 Cardiology & Respiratory Medicine, Hvidovre Hospital